Immunome (IMNM) Free Cash Flow Growth (3y) (2022 - 2026)

Immunome (IMNM) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.05%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 31.07%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 14.71%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Immunome 2.59 Bn 2.00 Bn - -65.99%

Historic Data

Download Data
DateValue
Mar 31, 2026 -65.99%
Dec 31, 2025 -97.39%
Sep 30, 2025 -81.02%
Jun 30, 2025 -78.77%
Mar 31, 2025 -107.14%
Dec 31, 2024 -84.45%
Sep 30, 2024 -105.08%
Jun 30, 2024 -94.41%
Mar 31, 2024 -48.86%
Dec 31, 2023 -42.07%
Sep 30, 2023 -47.34%
Jun 30, 2023 -47.36%
Mar 31, 2023 136.94%
Dec 31, 2022 -36.67%